
Gilead shares drop 4% after failure of NASH drug to meet primary endpoint
pharmafile | February 12, 2019 | News story | Manufacturing and Production | Gilead, Shares, fatty liver disease, nash, selonsertib
Gilead’s treatment for the progressive fatty liver disease, NASH, has failed to meet its primary goal in a phase 3 trial, causing shares in the company to fall by as much as 4%.
Gilead’s treatment for Nonalcoholic Steatohepatitis (NASH), a drug called selonsertib, did not meet its primary endpoint in a randomised, double-blind, placebo controlled Phase 3 trial involving 877 patients.
Of the 877 patients, 14.4% of those receiving 18 mg of selonsertib, compared to 12.5% who received 6mg achieved a ≥ 1-stage improvement in fibrosis after 48 weeks of treatment. Meanwhile 12.8% of those who received the placebo achieved similar results.
“While we are disappointed that the STELLAR-4 study did not achieve its primary endpoint, we remain committed to advancing therapies for patients with advanced fibrosis due to NASH, where there is a significant unmet need for effective and well-tolerated treatments,” said Dr John McHutchison, Chief Scientific Officer, Head of Research and Development, Gilead.
Analysts have projected the NASH market to be worth between $20 billion and $35 billion as cases of the fatty liver disease are on the rise.
Louis Goss
Related Content

Gilead’s HIV treatment meets primary trial endpoint
Gilead has announced positive topline results from its phase 3 ARTISTRY-2 trial, which evaluated a …

Gilead announces first shipments of HIV prevention drug to Eswatini and Zambia
Gilead has announced the first shipments of its HIV prevention drug lenacapavir to Eswatini and …

Gilead shares phase 3 results from HIV prevention trial
Gilead Sciences has announced results from an interim analysis of its pivotal, phase 3 PURPOSE …






